Abstract
The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.
Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity
Current Clinical Pharmacology
Title: Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Volume: 6 Issue: 3
Author(s): Priti Patel and Sandy Srinivas
Affiliation:
Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity
Abstract: The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.
Export Options
About this article
Cite this article as:
Patel Priti and Srinivas Sandy, Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma, Current Clinical Pharmacology 2011; 6 (3) . https://dx.doi.org/10.2174/157488411797189442
DOI https://dx.doi.org/10.2174/157488411797189442 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Medical Treatment Of Elderly Patients With Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Maternal Serum Uric Acid as a Predictor of Severity of Hypertensive Disorders of Pregnancy: A Prospective Cohort Study
Current Hypertension Reviews Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Current Drug Safety Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Beta-propellers: Associated Functions and their Role in Human Diseases
Current Medicinal Chemistry Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia
Current Neurovascular Research From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design